Anthera saw its shares tank after hours as the biotech announced yet another failed study, this time for its late-stage trial for a GI candidate in cystic…
Shares in Seattle Genetics were down 15% today after it announced the FDA had slapped both partial and full clinical holds on several of its early-stage trials.
AveXis was down 6% today as Biogen and partner Ionis got an early present in the form of the first-ever approval for a drug that helps children with spinal…
The FDA cleared AirXpanders’ wireless tissue expander system, which provides patients who choose to undergo breast reconstruction with an at-home, needle-free…
With 2016’s wild-card Republican primary candidate becoming 2017’s POTUS, the list of outstanding questions confronting biotech this year is particularly long.
At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017…
It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…
This year will not go down as a classic for biotech IPOs; in fact, it’s been pretty dismal, with a report by Renaissance Capital out in the summer showing that…
